fbpx Skip to main content
 

Search

Janssen Search

Search results

256 SEARCH RESULTS FOR

faxtor 11 phase 3

Not finding what you're looking for? Visit Janssen in your country.
PAGE 3 OF 26

Pages

Oct 23, 2023 Spain Phase 3 MARIPOSA-2 Study Shows RYBREVANT ® (amivantamab-vmjw) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFR-Mutated Non-Small Cell ...

Sep 14, 2024 Spain Median duration of response reaches 7.4 months with combination treatment in patients with aggressive form of disease New results show potential of RYBREVANT ® beyond lung cancer BARCELONA, September 14, 2024 – Johnson & Johnson ...

Sep 08, 2023 Belgium Pending approval, erdafitinib, an investigational, once-daily oral pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, [1] will become the first therapy targeting FGFR alterations [2] in patients with metastatic ...

Sep 14, 2024 Spain Post-progression outcomes showed significant and sustained improvement for RYBREVANT ® plus standard of care versus chemotherapy alone BARCELONA, September 14, 2024 – Johnson & Johnson (NYSE:JNJ) today announced updated results from ...

Aug 18, 2023 Belgium Teclistamab, the first BCMA-targeting bispecific antibody to receive approval in Europe, maintained deep and durable responses, with reduced onset of Grade 3 or higher infections, in eligible patients with relapsed and refractory ...

Nov 27, 2023 Belgium The submission is supported by data from the Phase 3 MARIPOSA-2 study featured in a Late-Breaking Presidential Symposium session at the 2023 ESMO Congress and simultaneously published in Annals of Oncology [1], [2] Amivantamab plus ...

May 20, 2024 Washington, D.C. (May 20, 2024) – Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients with moderately to severely active ulcerative ...

Dec 11, 2023 United States Analysis from MonumenTAL-1 study showed patients with relapsed or refractory multiple myeloma treated with TALVEY™ were subsequently treated effectively with several classes of therapy, including CAR-T Additional presentations ...

Oct 06, 2023 Belgium Type II Extension of Indication Application is supported by data from PAPILLON, the first randomised Phase 3 study to read out in patients with NSCLC with EGFR exon 20 insertion mutations [i]   BEERSE, BELGIUM, 6 October, 2023 – The ...

May 31, 2024 New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program Longer overall survival, progression-free survival and duration of response shown with subcutaneous ...

256 SEARCH RESULTS FOR

faxtor 11 phase 3

Not finding what you're looking for? Visit Janssen in your country.
PAGE 3 OF 26

Pages